Consultation open on access to DMT for PPMS
Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to delay time to wheelchair by 7 years allowing people to continue working, supporting their families and whānau, and living well. The criteria under consultation is for …